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INTRODUCTION
Familial hypophosphatemic rickets (FHR) is defined as a
group of disorders caused by a defect in renal phosphate trans-
port, leading to phosphate wasting and hypophosphatemia.
FHR is also characterized by the abnormal regulation of vita-
min D metabolism, resulting in inappropriately normal 1,
25-dihydroxyvitamin D concentrations despite hypophosph-
atemia (1). X-linked hypophosphatemic rickets (XLH; MIM
307800), the most common form of FHR, is characterized by
rickets and osteomalacia, lower-extremity deformities, short
stature, bone pain, dental abnormalities, and abnormal vitamin
D metabolism (2). Other less common forms of FHR include
autosomal dominant hypophosphatemic rickets (ADHR), he-
reditary hypophosphatemic rickets with hypercalciuria, and
tumor-induced osteomalacia.
XLH results from loss-of-function mutations in the PHEX
gene (phosphate-regulating gene with homologies to endopep-
tidases on the X chromosome), located on Xp22.1 (3). PHEX
is a member of the M13 family of type II cell-surface-mem-
brane zinc-dependent proteases, which include neprilysin
(NEP), two endothelin-converting enzymes (ECE-1 and -2),
the KELL antigen, and damage-induced neuronal endopep-
tidase/X-converting enzyme (4). PHEX cDNA has been clon-
ed (5) and consists of 22 exons spanning 2,247 bp of genomic
sequence. Seventeen of the 22 exons are less than 130 bp long
(2). PHEX and NEP share conserved genomic structures. Like
NEP, PHEX includes a short N-terminal tail, a single N-ter-
minal hydrophobic region corresponding to a transmembrane
domain, a highly conserved zinc-binding domain in exons 17
and 19, and several conserved cysteine residues and amino acids
that, in NEP, are involved in its catalytic activity (1).
Several studies have identified mutations in the PHEX gene
in individuals with XLH. Recently, we studied the clinical
and molecular characteristics of Korean patients with XLH.
In this report, we describe eight different PHEX mutations
identified in 15 unrelated Korean patients with hypophos-
phatemic rickets, including five novel mutations.
MATERIALS AND METHODS
Subjects
This study included 15 patients and five of their family mem-
bers, aged from 20 months to 60 yr (average, 22 yr). Of the
15 patients, five had a family history of XLH, four were spo-
radic cases, and the other six were unknown. Diagnoses were
made based on clinical, radiological, and laboratory findings
by specialists at the Korea University Guro Hospital. Of the
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PHEX Gene Mutations and Genotype-Phenotype Analysis of Korean
Patients with Hypophosphatemic Rickets
X-linked hypophosphatemic rickets (XLH) results from mutations in the PHEX gene.
Mutational analysis of the PHEX gene in 15 unrelated Korean patients with hypo-
phosphatemic rickets revealed eight mutations, including five novel mutations, in nine
patients: two nonsense mutations, two missense mutations, one insertion, and three
splicing acceptor/donor site mutations. Of these, c.64G>T, c.1699C>T, c.466_467
insAC, c.1174-1G>A, and c.1768+5G>A were novel mutations. To analyze the corre-
lation between genotype and phenotype, phenotypes were compared between gro-
ups with and without a mutation, in terms of mutation location, mutation type, and
sex. Skeletal disease tended to be more severe in the group with a mutation in the
C-terminal half of the PHEX gene, but no genotype-phenotype correlation was detect-
ed in other comparisons. Further extensive studies of the PHEX gene mutations and
analyses of the genotype-phenotype relationships are required to understand PHEX
function and the pathogenesis of XLH.
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Accepted : 7 March 200715 patients, four were male and 11 were female. Overall, there
were five male and 15 female individuals (including family
members). Five patients were young children. Of the five fam-
ilymembers evaluated, three were related to patient 1-1 (moth-
er, maternal aunt, and cousin) and two to patient 7-1 (moth-
er and maternal aunt) (Fig. 1).
For phenotypic analyses, the medical records and histories
of the patients were reviewed retrospectively. The severity of
the skeletal disease was assessed by orthopedic surgeons and
was classified as mild, moderate, or severe (Table 1) (1). Oste-
otomies were performed in patients who complained of gait
disturbance caused by either pain or fatigue. For the two pa-
tients with affected family members, the families were ana-
lyzed as a unit. They were classified as having mild disease if
all members had mild disease, as having moderate disease if
at least one member had moderate disease, or as having severe
disease if at least one member had severe disease.
Although there are no widely accepted criteria with which
to describe the severity of dental disease manifestations in pa-
tients with rickets, we simplified the assessment of dental di-
sease severity by describing it in terms of the number of den-
tal abscess lesions and the treatments performed for these ab-
scesses (Table 1). The data on dental diseases were collected
based on the histories of the patients.
Mutation analysis
Informed consent for DNA analysis was obtained from the
patients or their parents, depending on the patient s age. Ge-
nomic DNA was extracted from the peripheral blood using
the G-DEXTM‚ II Genomic DNA Extraction Kit (Intron,
Seongnam, Korea), according to the manufacturer’s proto-
col. Screening for mutations was performed with PCR ampli-
fication and direct sequencing. All 22 exons of the PHEX
gene, including at least 40 bp of the exon-intron flanking
regions, were amplified by PCR. Sequencing was performed
with a DynamicTM‚ ET Dye Terminator Kit (GE Healthcare,
Buckinghamshire, U.K.) and a MegaBACE 500 Genetic
Analyzer (GE Healthcare), according to the manufacturer’s
instructions. Base calling of the sample files was performed
with Cimarron Base Caller version 3.12 software (GE Health-
care).
The PHEX genes of 50 normal female individuals were
also analyzed to confirm that the sequence variations in the
PHEX gene identified in this study were not polymorphisms
but real pathogenic mutations. Novel mutations were defined
by their absence from the Human Gene Mutation Database
(http://www.uwcm.ac.uk/uwcm/mg/hgmd0.html) and from
mutations previously reported in PubMed (http://www.ncbi.
nlm.nih.gov/PubMed/). The functional consequences of novel
splice variants were predicted with the Automated Splice Site
Analyses program on the web (https://splice.cmh.edu/) (6).
Statistical analysis
The Wilcoxon rank-sum test and the two-tailed Fisher’s
exact test were used to calculate p values and to determine
whether the differences between the phenotypes of the geno-
type groups were statistically significant. We used a signifi-
cance level of p<0.10 because the sample size was small, in
accordance with previously published analyses of small sam-
ples (1, 7).
RESULTS
In a total of 15 patients, the average ages at onset and diag-
nosis were 31 months and 90 months, respectively. The male:
female ratio among the patients was 4:11 (Table 2, 3). La-
boratory findings were available for 10 patients: seven patients
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N/A, not applicable.
Classification Skeletal disease Dental disease
None N/A No dental abscess
Mild No or mild bowing and  Less than two dental
no history of osteotomy abscess lesions
Moderate Moderate bowing and/or More than three dental
a history of osteotomy abscess lesions and/or
extraction
Severe Severe bowing and/or  Severely malpositioned teeth 
a history of osteotomy with orthodontic treatment
Table 1. Classification of phenotypic severity of skeletal and den-
tal diseases
Fig. 1. Pedigrees of patients 1 (A) and 7 (B) with X-linked hypophos-
phatemic rickets.
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B
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with a PHEX gene mutation and three patients without a
PHEX gene mutation. The mean total serum calcium and
phosphorus levels for those 10 patients were 9.2±0.4 mg/dL
and 2.2±0.8 mg/dL, respectively.
Eight different mutations in the PHEX gene were detected
in nine patients of the 15 unrelated Korean patients (60%).
Of these, c.64G>T, c.1699C>T, c.466_467insAC, c.1174-
1G>A, and c.1768+5G>A were novel mutations identified
in this study (Fig. 2).
Inspection of the mutations revealed that c.1363G>T (p.
Glu455X) and c.1699C>T (p.Arg567X) were nonsense muta-
tions, and that c.1601C>T (p.Pro534Leu) and c.64G>T (p.
Ala22Ser) were missense mutations. One mutation, c.466_467
insAC, was an insertion that causes a frameshift leading to a
downstream stop codon at amino acid 222. Three mutations,
c.1174-1G>A (IVS10-1G>A), c.1768+5G>A (IVS17+5G
>A), and c.1965+1G>A (IVS19+1G>A), occur at splicing
acceptor/donor sites; c.1174-1G>A was detected in two unre-
Familial
Family 
Sex/
Age at
Age at Predicted
Exon/ Osteo- Dental No. rela-
history
age
onset
diagnosis Mutation* amino acid
intron
Bowing
tomy severity tionship (yr) (yr) change
Treatment
Phos-
phate
Vitamin
D
1-1 Proband Y F/18 5 yr 14 c.1363G>T p.Glu455X 12 Severe Y Mild Y Y
1-2 Mother Y F/40 5 yr 37 c.1363G>T p.Glu455X 12 Severe Y Mild Y Y
1-3 Maternal Y F/32 6 yr 28 c.1363G>T p.Glu455X 12 Mild Y Severe Y N
aunt
1-4 Cousin Y M/22 2 yr 17 c.1363G>T p.Glu455X 12 Mild Y Moderate Y Y
2-1 Proband N F/18 birth 4 c.1601C>T p.Pro534Leu 15 Moderate Y None N Y
3-1 Proband U F/34 3 yr 32 c.466_467 Frameshift 5 Mild Y Moderate Y Y
insAC
�
4-1 Proband U F/39 1-2 yr 2 c.1174-1G>A
� Splicing IVS10 Severe Y Severe Y Y
variant
5-1 Proband U F/16 3 yr 3 c.1174-1G>A
� Splicing IVS10 Moderate Y Moderate Y Y
variant
6-1 Proband U F/3 2 yr 2 c. 64G>T
� p.Ala22Ser 1 Mild N Moderate N Y
7-1 Proband Y F/33 <1 yr 30 c.1699C>T
� p.Arg567X 16 Severe Y Severe Y Y
7-2 Mother Y F/60 38 yr 44 c.1699C>T
� p.Arg567X 16 Moderate Y Mild N/A N/A
7-3 Maternal Y F/47 U 11 c.1699C>T
� p.Arg567X 16 Mild N Mild N/A N/A
aunt
8-1 Proband U F/20 5 yr 5 c.1768+5
� Splicing IVS17 Mild N None N/A N/A
variant
9-1 Proband Y M/15 10 yr 10 c.1965+1G>A Splicing  IVS19 Severe Y Moderate N Y
variant
Table 2. Genotype and phenotype data for patients and family members with a PHEX gene mutation
*Reference sequences for PHEX, gDNA U82907, cDNA NM_000444. Mutation numbering is based on cDNA sequences. +1 corresponds to the first
base of the translation initiation codon. 
�
Novel mutations identified in this study. N/A, not applicable. U, unknown.
No. Family history Sex/age
Age at Age at
Bowing Osteotomy
Dental
onset diagnosis severity
Treatment
Phosphate Vitamin D
10-1 N M/4 yr 2 yr 3 yr Severe Y Moderate Y Y
11-1 N M/4 yr 2 yr 2 yr Severe Y Mild Y Y
12-1 Y F/5 yr 2 yr 2 yr Mild N Mild N N
13-1 U F/20 mo 16 mo 16 mo Mild N None N N
14-1 N F/5 yr Birth 1 yr Mild N None Y Y
15-1 Y M/14 yr 13 mo 13 mo Severe Y Severe Y Y
Table 3. Genotype and phenotype information for patients without a PHEX gene mutation
U, unknown.
Mutation (+) Mutation (-)
p value (n=9) (n=6)
Sex ratio (M:F) 1:8 3:3 > 0.1
Family history (+:-) 3:1 2:3 > 0.1
Age at onset (months) 64±71.2 17±9.5 0.049
Skeletal disease > 0.1
Mild 3 3
Moderate to severe 6 3
Dental disease > 0.1
None to mild 2 4
Moderate to severe 7 2
Table 4. Genotype-phenotype correlations in patients with and
without a PHEX gene mutationlated Korean patients. Two mutations, c.64G>T and c.466_
467insAC, are located in the N-terminal half and the other
six mutations are in the C-terminal half of the PHEX protein
(Fig. 3). For novel splice variants, automated splicing muta-
tion analysis predicted that the c.1174-1G>A variation de-
creases the binding energy of the natural splice acceptor site
to 0.5% and thus abolishes the site, and that the c.1768+5G>
A variation decreases the binding energy of the natural splice
site to 8.7% of its initial energy and thus weakens the origi-
nal donor splice site.
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Fig. 3. Mutations of the PHEX gene identified in Korean patients with X-linked hypophosphatemic rickets. The putative transmembrane domain
(TM), cysteine residues (C), and zinc-binding domains (Z) are shown below the boxes of the 22 exons. Novel mutations found in this study
are shown in bold.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
TM
5 -UTR 3 -UTR
NH2
c.58C>T
c.64G>T c.1174-1G>A
c.1768+5G>A c.1363G>T
c.1965+1G>A
c.1601C>T
c.466_467insAC
c.1715G>A c.2242C>T
c.2171_2172delTT
c.1996_2008delCAGGGACTTGAGG
c.1952_1963delGGGAAGCTTTTA
CC CC C C C C ZZ C C C C O O H
c.1699C>T
A
Normal
Mutation
c.64G
c.64G>T
G G CA C T C G A A  T T G C C C T G G T C G T G T T T  G TC GG
A GGC A C  TC G A A T T N CCC T G GT C GTG T T T G T C GGT
200 210
210 220 230 240
220
E
Normal
Mutation
c.1768+5G
c.1768+5G>A
GACATG AATTTACACATGG ATTTGAT AAT AA TGG T AAGTAC
AATTTACACATGGATTTGATAATAATGGTAAA TACCGGTTCATTTTATA
150 160 170 180
160 170 180 190 200
C
Normal
Mutation
c.1174-1G
c.1174-1G>A
CAGGTAA T C CAGGGGACCA CAA CTTTGCTG CCT CA ATGGG
CAGGTAA T CCA GGGGACCA CAA CTTTGCTGCC T CAATGGG
170 180
170 180 190 200
190 200
D
Normal
Mutation
c.1699C
c.1699 C>A
G   G  A AC  A G  AA   T A T CC    T C G   G  T G  A G T AA   A
G  G  A A C  A G  AA   T A T CC   T C G  G  T G A G T AA   A
150
140 150 160
160
B
Normal
Mutation
c.466
c.466 insAC
GCAGA TGCCAA GCCACT GCT ACACA TCC T ACGGCATTCAC
GCA GA  T GCC AA   GCC  AC A TCGT GAC TA C A C TCC TC TCAT AG CG GAGTAT C T ATCN CC TCTTT C T
170 160 150 140
140 150 160 170 180 190 200
Fig. 2. Direct sequencing results demonstrate novel mutations, c.
64G>T (A), c.466insAC (B), c.1174-1G>A (C), c.1699C>T (D), and
c.1768+5G>A (E), in the PHEX gene in patients with X-linked hypo-
phosphatemic rickets.The phenotypes of the 15 patients and of all available fam-
ily members (including five family members of two patients)
were analyzed. The average age at onset was 64 months in
the group with a PHEX mutation and 17 months in the group
without a PHEX mutation (p=0.049; Table 4). No signifi-
cant correlation was found between the severity of the skele-
tal or dental disease and the mutation type (Table 5). Skele-
tal disease was more severe in the group with a mutation in
the C-terminal half of the protein (p=0.083) (Table 5).
DISCUSSION
XLH is the most common form of FHR and results from
a mutation in the PHEX gene. In our study, the mutation de-
tection rates in the PHEX gene were 60% in familial cases
and 25% in sporadic cases among patients with XLH. These
are similar to the results of previous studies: 51-86% in famil-
ial cases and 22-57% in sporadic cases (1, 2, 8-10), except for
one Finnish study, in which the mutation detection rate was
100% for familial cases and 93% for sporadic cases (11). The
lower mutation detection rate in sporadic cases might be ex-
plained by the fact that the sporadic disease can be caused by
other types of hypophosphatemic rickets, such as ADHR (1).
Thus, patients without a PHEX gene mutation should be
screened for mutations in fibroblast growth factor 23 (4, 12).
Because only the 22 exons were screened for mutations in our
study, mutations in the promoter, introns, 5′ -untranslated re-
gion, 3′ -untranslated region, and target sequences of miRNAs
might have been overlooked (10, 13).
The c.1601C>T mutation has been observed in many stud-
ies (1, 2, 8-10, 14). This region may be prone to mutation, as
suggested by Dixon et al. (9). Pro534 is encoded by one of 47
CpGs in the PHEX gene (15). The p.Pro534Leu mutation
seems to affect the local hydrophobicity of the gene product,
because leucine is aliphatic (2), and the substituted proline is
conserved in ECE-1 and the KELL antigen (8). The c.64G>
T mutation, a new mutation detected in this study, occurs at
the site of the putative transmembrane domain. No mutation
was identified in the putative transmembrane domain in a pre-
vious study (9).
The marked difference in the average age at onset between
the groups with and without a PHEX mutation may be the
result of the small sample size and the late age at onset of one
family member, subject 7-2 in Table 2. Severe phenotypes
usually begin to manifest at an earlier age than do mild phe-
notypes. However, early mean age of onset and disease severity
were not correlated in this study. Furthermore, the differ-
ence in the average age at onset between the groups with and
without a PHEX gene mutation was not statistically signif-
icant in a previous study (10). A larger sample size is required
to confirm these data.
The number of mutations in the C-terminal half of PHEX
was 3.5 times greater than the number in the N-terminal half
in this study, and 1.7 times greater than that reported by Fi-
lisetti et al. (15). Patients with a mutation in the C-terminal
half of the protein had more severe skeletal disease in this study.
The N-terminal region contains the cytoplasmic domain, trans-
membrane domain, and five conserved cysteine residues,
whereas the C-terminal region contains two zinc-binding mo-
tifs in exons 17 and 19, five conserved cysteine residues, and
the catalytic site (2, 5, 15, 16). No agreement has yet been
reached regarding the correlation between the disease pheno-
types and PHEX mutation locations, including those in this
study (1, 8, 17). Holm et al. (1) identified a trend between
truncating mutations and more severe skeletal disease in a
familial group (p=0.072). However, Cho et al. (10) reported
no correlation between phenotype and mutation type, con-
sistent with the results of this study.
The gene dosage effect was also analyzed in the nine patients
with PHEX mutations, but no significant correlation was
found (data not shown). Because the sample was small, we did
not divide the group into prepubertal and postpubertal age
groups. However, Holm et al. (1) reported a trend towards an
association between male sex and more severe dental disease.
Because XLH is inherited as an X-linked dominant trait, fe-
males should usually be less severely affected than males. How-
ever, no gene dosage effect was observed in this study or in a
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Mutation
Types Locations
Truncating (n=3) Nontruncating (n=6) N-terminal half (n=2) C-terminal half (n=7)
Sex ratio (M:F) 0:3 1:5 0:2 1:6
Family history (+:-) 2:0 1:1 0:0 3:1
Age at onset (months) 107±107.8 43±42.7 30±6.0 74±29.8
Skeletal disease
Mild 2 1 2 1
Moderate to severe 4 2 0 6*
Dental disease
None to mild 2 0 0 2
Moderate to severe 4 3 2 5
Table 5. Genotype-phenotype correlations in patients with a PHEX gene mutation in terms of mutation type
*p<0.1 (0.083); p>0.1 for other parameters.previous study (10), although our sample was too small to allow
any conclusion to be drawn. Previous studies have indicated
that the PHEX gene is subject to random inactivation, but
it has also been reported that some alleles escape inactivation
(18, 19).
Hypophosphatemic rickets often exhibit high pulp horns,
large pulp chambers, and dentinal clefts. Although odonto-
blast function is normal, hypophosphatemia leads to dysplas-
tic and poorly mineralized areas of the interglobular dentin
(20). We classified dental diseases according to the number of
dental abscess lesions and the treatments performed for these
abscesses. However, no genotype-phenotype correlation was
detected in comparisons of dental disease severity.
In this study, although skeletal disease tended to be more
severe in the group with a mutation in the C-terminal half
of PHEX, the sample size was too small to draw a definitive
conclusion. Therefore, identification of the mutation in the
PHEX gene may have a limited prognostic value in patients
with XLH. Other factors may exist that determine the phe-
notypes of patients with XLH.
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